Preservation of Fertility and the Impact of Subsequent Pregnancy in Patients With Premenopausal Breast Cancer

Park, Meyeon; Davidson, R.; Fox, Kevin R.

doi:10.1053/j.seminoncol.2006.08.015

Cited by 13 publications

(9 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…when adverse pregnancy outcomes were analyzed with respect to chemotherapy alone, radiotherapy alone, or combined therapy. Valentgas et al [56] found that miscarriages occurred in 24% of 53 breast cancer survivors compared with 18% of control women without breast cancer of similar ages (Table 4) [43,56,58,59]. Other authors reported that cytotoxic drug exposure had no deleterious effects on subsequent pregnancies in terms of miscarriages or congenital malformation [43,[57][58][59][60][61].…”

Section: Pregnancy After Chemotherapymentioning

confidence: 93%

Fertility outcome of breast cancer and Hodgkin’s lymphoma female survivors: a growing clinical challenge for gynecologists and oncologists

Gadducci

Tana

Sergiampietri

et al. 2013

Gynecological Endocrinology

View full text Add to dashboard Cite

The issue of taking into consideration future fertility in young women with breast cancer and Hodgkin's lymphoma [HL] will become more and more common and represent a growing clinical challenge for gynecologists and oncologists. The present paper will review literature data on the attempts of preventing chemotherapy-induced ovarian damage in these women and on their fertility outcome. Gonadotropin-releasing hormone [Gn-RH] agonists have been widely investigated as agents able to prevent ovarian failure in animal models and in humans. The majority of the studies on women with breast cancer and HL have shown a protective effect of Gn-RH agonists. A recent meta-analysis of five randomized trials, including 528 premenopausal breast cancer patients, revealed that relative risk [RR] of developing premature ovarian failure within one year was 0.40 (95% confidence interval [CI] = 0.21-0.75) for the women who received Gn-RH agonists with chemotherapy compared to those who received chemotherapy alone. However, the concurrent administration of Gn-RH agonists during chemotherapy appeared to have no effect on spontaneous pregnancy rates. Limited information are available about pregnancies in breast cancer and HL survivors, but the current literature appears to show no apparent increase in pregnancy complications, spontaneous abortions, or congenital abnormalities compared to general obstetric population.

show abstract

Section: Pregnancy After Chemotherapymentioning

confidence: 93%

Fertility outcome of breast cancer and Hodgkin’s lymphoma female survivors: a growing clinical challenge for gynecologists and oncologists

Gadducci

Tana

Sergiampietri

et al. 2013

Gynecological Endocrinology

View full text Add to dashboard Cite

show abstract

“…A l'heure actuelle, les données de la littérature ne nous permettent ni d'encourager une grossesse ni de la déconseiller formellement [2], le rôle de l'information régulière, évolutive et loyale est ici encore déterminant. En pratique, le délai conseillé est d'environ 2 ans après le diagnostic en cas de petite tumeur (T1 T2) infiltrante de bon pronostic, et de 3 ans en cas de facteurs péjoratifs [44]. Un cas particulier est celui des patientes présentant un cancer du sein triple négatif dont on connaît le risque élevé de récidive à court terme (les 3 premières années post-thérapeutiques) avec un risque plus faible de récidive au-delà de ce délai.…”

Section: Délai Entre Le Traitement Du Cancer Et La Conceptionunclassified

Grossesse après cancer : pour qui et quand ?

Margulies

Selleret²,

Zilberman³

et al. 2015

Bulletin du Cancer

View full text Add to dashboard Cite

Planning a pregnancy for patients with a history of cancer, including breast cancer, is a clinical situation that becomes more and more common. Several specific items are to be discussed: decrease of fertility after cancer treatment, fertility preservation options, impact of pregnancy on cancer recurrence risk and appropriate interval between cancer and pregnancy. Programming pregnancy after cancer is doable in a multidisciplinary setting, and begins at cancer diagnosis to anticipate the various specific pitfalls. Favor adequate oncologic care remains the leading rule.

show abstract

“…Although tamoxifen and letrozole are both contraindicated during pregnancy, multiple studies show that their use prior to conception poses no risk to the oocyte, embryo, or fetus [66][67][68][69]. Moreover, embryos that are cryopreserved are never even exposed to these drugs because the fertilization occurs in vitro, and they are not transferred to the uterus until after completion of therapy.…”

Section: Medical Strategiesmentioning

confidence: 99%

Fertility Preservation Options for Female Cancer Patients: A Systematic Review

Dayal¹

2012

J Fertiliz In Vitro

View full text Add to dashboard Cite

Advances in cancer detection and treatment have resulted in an increasing amount of long-term survivors who are left to deal with the adverse effects of their treatments. Fortunately, progress in fertility preservation technologies has been paralleling the trend in improving cancer outcomes. Because of the variations in type and dose of chemotherapy or radiation, the type of cancer, the time available before treatment initiation, and the patient's age and partner status, each case is unique and requires a different strategy for fertility preservation. The field of fertility preservation is growing rapidly. It is the goal of this paper to review some of the options, their success rates, and their limitations, so physicians can provide appropriately counsel and expeditiously refer their pre-menopausal patients diagnosed with cancer to a fertility specialist.

show abstract

Preservation of Fertility and the Impact of Subsequent Pregnancy in Patients With Premenopausal Breast Cancer

Cited by 13 publications

References 81 publications

Fertility outcome of breast cancer and Hodgkin’s lymphoma female survivors: a growing clinical challenge for gynecologists and oncologists

Fertility outcome of breast cancer and Hodgkin’s lymphoma female survivors: a growing clinical challenge for gynecologists and oncologists

Grossesse après cancer : pour qui et quand ?

Fertility Preservation Options for Female Cancer Patients: A Systematic Review

Contact Info

Product

Resources

About